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Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor
antagonist on cyclophosphamide induced vomiting in the ferret
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'Department ofPhysiology, St Georges Hospital Medical School, London SW17 ORE, UK; and 2Section ofMedicine, Institute of
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Summary A new group of selective 5HT3 antagonists are proving to be effective anti-emetics for cytotoxic
and radiation induced vomiting in both animal models and man. Current anti-emetic regimens often benefit
from combination therapy, in particular the efficacy of metoclopramide (which can be a weak 5HT3
antagonist), can be improved by combination with dexamethasone, another anti-emetic. Hence it was of
interest to evaluate whether a 5HT3 receptor antagonist GR38032F could be improved by combination with
dexamethasone. Vomiting induced by cyclophosphamide in the ferret was observed after pre-treatment with
dexamethasone alone or in combination with GR38032F. Animals were also observed for signs of 'nausea'.
Dexamethasone alone proved a weak anti-emetic in this system but did have significant effects on 'nausea'.
GR38032F has previously been shown to be capable of totally controlling emesis due to cyclophosphamide in
the ferret. Here a dose of GR38032F that is not 100% effective was employed; this was shown to have effects
on 'nausea' but most interestingly its anti-emetic action was increased by combination with dexamethasone.
This may be important for the minority of patients whose vomiting is not completely controlled by GR38032F
alone.
Nausea and emesis are the most distressing side-effects of
cancer chemotherapy (Coates et al., 1983), causing anxiety,
demoralisation of the patient and, in extreme cases, patient
non-compliance (Laszlo, 1981). The actual trigger(s) causing
this nausea and vomiting is complex,-probably involving the
direct effects of the drugs, their metabolites or substances
which they release at both peripheral and central sites (for
review see Andrews & Hawthorn, 1988).
One of the most effective and widely used anti-emetics is
metoclopramide (for review see Gralla, 1983). Many anti-
emetic regimens benefit from combination therapy and in this
context the action of metoclopramide is enhanced by the
concomitant administration of dexamethasone (Bruera et al.,
1982; Allan et al., 1984; Palmer & Colls, 1987). However,
even this combination is far from totally effective. Following
the demonstration that metoclopramide was more effective at
high doses (Gralla et al., 1981) and that high dose metoclop-
ramide showed antagonism at the 5HT3 (or M) type receptor
(Fozard, 1984) a new group of selective 5HT3 receptor an-
tagonists, then recently developed (Brittain et al., 1987; Fake
et al., 1987; Fozard, 1984; Richardson et al., 1985) were
investigated as possible anti-emetics. Their effectiveness has
surpassed other anti-emetic therapies in both animal models
(Miner & Sanger, 1986; Miner, Sanger & Turner, 1987; Haw-
thorn et al., 1988; Costall et al., 1986; Stables et al., 1987;
Bermudez et al., 1988) and human studies (Cunningham et
al., 1988; Liebundgut et at., 1988; Carmichael et al., 1988).
So far they have only been employed singly and hence it was
of interest to evaluate whether the effect of a 5HT3 receptor
antagonist, GR38032F (Glaxo), against cyclophosphamide-
induced vomiting in the ferret could be improved by com-
bination with dexamethasone. The ferret is an animal that is
well established for studies of emesis (Florczyck et al., 1982;
Gylys & Gidda, 1986; Hawthorn et al., 1988; King, 1988;
Tuor et al., 1988) shows behavioural perturbations which
may indicate nausea (Bermudez et al., 1987; Hawthorn &
Andrews, 1988) and is a good predictive model of anti-
emetics for man (Miner et al., 1987). We employed a dose of
GR38032F that had been established as effective in delaying
but not reducing the emesis in this model (Stables et al.,
1987) and observed whether this was influenced by dex-
amethasone. We also studied the effect of dexamethasone
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alone. As this anti-emetic has not been assessed in the ferret
before, this would further extend our knowledge of the ferret
as a suitable model for anti-emetic studies.
Materials and methods
Animals and drugs
The animals used were albino or fitch ferrets (Mustela pu-
torius furo L.) of either sex weighing between 500 and
1,200 g. They were housed singly under a 12-h light cycle and
fed ad libitum on a standard carnivore diet. Food was with-
drawn the night before experimentation. The following morn-
ing they were placed in a clear perspex observation pen
(70 cm x 40 cm x 60 cm) and filmed on video tape in the
absence of any observers. After a 40 min period the appro-
priate pre-treatment ofGR38032F (Glaxo) or dexamethasone
(Oradexon, Organon) was administered subcutaneously into
the shoulder. GR38032F was dissolved in 154 mM NaCI, dex-
amethasone was supplied as the sodium phosphate in
aqueous solution. The total injection volume was < 1.0 ml.
The animals were returned to the observation pen and
given milk to drink ad libitum; this facilitated subsequent
observation of emesis. Filming continued for a further
30-40 min, after which they were injected intra-peritoneally
with 200 mg kg-' cyclophosphamide; this is the EDIoo (in
terms of producing emesis) in this species (Hawthorn et al.,
1988). Cyclophosphamide (Sigma) was dissolved in alcohol
(1 mg ml-') and diluted with 154 mM NaCl. The final injec-
tion volume was 2-3 ml. Filming was continued for a further
4 h after which the animals were killed by an overdose of
pentobarbitone (Euthetal, May and Baker).
The groups investigated were controls, GR38032F 0.1 mg
kg-' alone, dexamethasone at 2 mg kg-' or 5 mg kg-' and
combinations of GR38032F 0.1 mg kg-' plus dexamethasone
2 mg kg-' or GR38032F 0.1 mg kg-' plus dexamethasone
5 mgkg-'.
Analysis ofvideo tapes
Later analyses of the video tapes quantified the number of
retches and vomits and the times at which they occurred. The
behaviour of the animals was assessed on a points system as
described previously (Hawthorn & Andrews, 1988) and
briefly outlined here. After considerable time analysing video
tapes and timing the number of occasions on which be-
haviour occurred we were able to draw up a points system
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for rating nausea. A point was awarded for the presence of
'nausea-related' behaviour and for the absence of behaviour
inhibited by 'nausea'. The positive behaviours were: slit eyed
appearance, licking, lying with the chin down on the floor,
running backwards, burrowing, walking on tiptoes, lying
totally prostrate with hind limbs plantar flexed, assuming a
posture like a recumbent 'S', walking while dragging their
belly along the ground, pressing the nose up against the side
of the pen, holding a very still position with the nose poin-
ting up in the air, being unable to sleep comfortably and
falling over. The behaviours scored for their absence were:
standing on hind legs, grooming, rolling over, sniffing and
playing with a drinking bowl. Using this system 'nausea'
could be reliably and reproducibly scored in ferrets which
had received emetic agents.
Control behaviour was assessed during the time period
20-40 min after the animals were placed in the observation
pen. This allowed a 20 min initial period for the animal to
become familiar with the pen. The 20 min period immediately
following pre-treatment was used to assess the behavioural
effects of GR38032F or dexamethasone. After administration
of cyclophosphamide the first 20 min period was not ana-
lysed and the observations were made at 20-40 min, as
20 min corresponds to the latency for cyclophosphamide to
induce emesis and the associated behavioural changes in this
species.
The patterns of retching and vomiting were obtained by
counting the number of retches or vomits that occurred in
each 10 min time interval following administration of the
cyclophosphamide, and taking an average of each 10 min
'bin' across groups. Total retches and vomits are quoted for
the entire 4 h observation period. Values are given as the
mean ± s.e.m. Even though the same animals were used for
sequential observations the combination of data from various
groups has necessitated the use of an unpaired t test.
Results
The amount of retching and vomiting in response to cyc-
lophosphamide with or without anti-emetic pre-treatment is
given in Table I. Control animals did not start to retch or
vomit until 18.0 ± 3.2 (mean ± standard error) min after ad-
ministration of the drug. GR38032F at 0.1 mg kg-' delayed
the onset of retching and vomiting to 99.0 ± 3.2 and
121.2 ± 30.0 min respectively. The increases in latency were
highly significant (P<0.005 and P<0.0005), although there
was no significant reduction in the total number of retches or
vomits over the 4 h observation period. The duration of
action of this dose of GR38032F for complete inhibition of
the retching and vomiting was 140 and 160 min respectively.
The lower dose of dexamethasone (2 mg kg-') tended to
increase the number of retches and vomits and decrease the
latency however this was not significant. The higher dose
(5mgkg-') also paradoxically reduced the latency to retch
and vomit significantly (P<0.05) and an initial early phase
of vomiting was noted, although the total retches and vomits
were reduced.
When the low dose of dexamethasone was administered
with the GR38032F it had no apparent additional effect and
the values obtained were very similar to those observed with
GR38032F alone, showing the increased latency and only
marginally decreased number of retches and vomits. In fact,
the presence of GR38032F seemed to counteract the tend-
ency for dexamethasone to decrease the latency and increase
the amount of vomiting.
The higher dose of dexamethasone had a marked effect.
Four animals were used in this group and one was complete-
ly protected, showing no retching or vomiting at all during
the 4 h of observation. A second animal was protected for a
considerable time and only had 15 retches and one vomit at
225 min. The other two animals both vomited but the total
vomits (4.5 ± 2.4) were significantly reduced compared to the
controls (P<0.05).
The patterns of retching and vomiting are shown in
Figures 1 and 2. By viewing the retches and vomits occurring
in 10 min time intervals the effects of the various drug pre-
treatments are more easily appreciated. Thus the ability of
GR38032F at this low dose to delay, but not diminish, the
retching and vomiting is quite clear. Dexamethasone at the
high dose had a pronounced effect on the later stage of
retching and especially vomiting. However, the effect of a
combination of GR38032F at 0.1 mg kg-' and dexametha-
sone at 5 mg kg-' was the most dramatic.
Table II shows the effects of the various drug treatments
on the 'nausea' experienced by the animals. The group receiv-
ing GR38032F plus the low dose of dexamethasone had not
been filmed on video and thus nausea scores cannot be given
for this group.
GR38032F (0.1 mg kg-') had a marked effect on the
nausea scores at 20 min after injection of cyclophosphamide
(5.5 + 0.9 compared to controls of 12.6 ± 0.6). Part of this
action is related to the ability of GR to delay the onset of
emesis, as when the animals were evaluated at 100 min dur-
ing periods of active emesis the nausea score was higher
(7.0 ± 0.9), although this was still significantly reduced com-
pared to controls at 20 min (P<0.001).
Dexamethasone also markedly reduced nausea scores and
this was dose related. These scores were measured at 20 min
as the latency to vomit was not appreciably altered compared
to controls and it is interesting to note that the scores are
reduced even though the animals were vomiting. The most
marked improvement in nausea was obtained with the com-
bination of GR38032F and the high dose of dexamethasone
compared to the controls both at 20 min (P<0.0001) and
100 min (P <0.001). Although the 'nausea' score had increased
by 100 min it was not significantly higher than at 20min.
Table I Retching and vomiting in response to cyclophosphamide in the presence of GR38032
and/or dexamethasone
Total retches Total vomits Latency retch Latency vomit
Control 95.4 ± 30.2 15.6 ± 3.0 18.0 + 3.2 18.0 ± 3.2
(n = 8)
GR 0.1 mg kg-' 86.7 ± 30.8 12.5 ± 3.5 99.0 ± 31 1b 121.2 ± 30*0b
(n = 4)
Dex 2 mg kg-' 101.6 ± 29.4 21.0 ± 4.3 14.7 ± 3.5 14.4 ± 3.5
(n = 7)
GR 0.1 mg kg-' 74.0 ± 33.7 12.2 ± 5.2 108.0 + 53 7aC 108.0 ± 53.7a
Dex 2 mg kg-'
(n = 4)
Dex 5 mg kg- ' 86.0 ± 26.0 10.0 ± 3.3 7.6 1.2a 8.5 ± 1.8
(n = 4)
Dex 5 mg kg-' 33.5 ± 15.5 4.5 ± 2.4a 84.7 ± 70.6 84.9 ± 60.6
GR 0.1 mg kg-' (4) (4) (3) (3)
ap<0.05 compared to control. bp<0.0005 compared to control.
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Figure 1 Retching in response to cyclophosphamide 200 mg kg-' i.p. alone or after pretreatment with varying doses of GR38032F
or dexamethasone. The anti-emetics were given alone or in combination as shown on the graphs. Results are plotted as mean ±
s.e.m. for the number of retches in each 10 min of the total observation period. The number of animals in each group is given in
Table I.
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Figure 2 Vomiting in response to cyclophosphamide 200mgkg-' i.p. Details are as in Figure
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Table II Nausea scores produced by cyclophosphamide after various anti-emetic
treatments
Plus cyclo at Plus cyclo at
Control 20-40 min 100-120 min
No treatment 3.1 0.3c 12.6 ± 0.6
(15) (7)
GR 0.1 mg kg-' 3.25 ± 1.1 5.5 ± 0.9c 7.0 ± 0.9b
(4) (4) (4)
Dex2mgkg-' 3.4±0.6 10.2±0.7a
(5) (5)
Dex 5mg kg-' 27.5 ± 0.25 5.2 ± 1.0b
(4) (4)
GR/Dex 5mg kg- 2.25 ±0.5 4.5 ± 0.5c 6.7 ± 1.2b
(4) (4) (4)
ap<0.05compared tocyclo alone. bP<0.001 compared tocycloalone.cP<0.0001
compared to cyclo alone.
Discussion
In this study, in the ferret, we have shown that dexame-
thasone alone is a poor anti-emetic but has dose related
actions on 'nausea' and that a high dose of dexamethasone is
capable of potentiating the action of a sub-optimal dose of
GR38032F. Dexamethasone alone had no significant effect
on retching and vomiting but caused a decrease in the latency
which was significant and dose related. However, 'nausea'
appeared to be reduced. Nausea is a subjective experience
which cannot be extrapolated directly from man to animal
models but considerable information can be derived from
observing animal behaviour associated with emesis. Experi-
ence has shown quite reproducible patterns of behaviour in
animal models (Bermudez et al., 1988; Hawthorn & And-
rews, 1988) and we have previously demonstrated that assign-
ing a 'score' to behaviour gives a good index of the discom-
fort or 'nausea' experienced by the animal, which responds to
anti-emetic treatment (Hawthorn & Andrews, 1988).
In this study GR38032F was effective in reducing the
nausea experienced 20 min after cyclophosphamide. Part of
this effect was related to its action in delaying emesis, but it
also produced a marked effect on nausea even when the
animals were actively vomiting. This action of dexametha-
sone was dose related, which is important bearing in mind
that the choice of dose of dexamethasone in a clinical situta-
tion is empirical and few dose response studies have been
made. The combination of dexamethasone and GR38032F
reduced nausea even further, although the differences be-
tween GR38032F alone, at 20 min, dexamethasone alone and
the combination therapy were small. Dexamethasone is
known to produce 'feelings of well being' in man and our
results have been paralleled in the clinical situation where it
has been shown that the inclusion of dexamethasone with
lorazepam/metoclopramide combination increased the num-
ber of patients receiving cisplatinum who were free of nausea
from 16 to 50% despite only a small reduction in median
number of vomiting episodes from 7.6 to 6.1 (Palmer &
Colls, 1987).
In contrast to the weak activity of dexamethasone to
enhance the action of GR38032F on nausea, its ability to
potentiate the antiemetic activity of GR38032F was pro-
nounced, and exceeded what could be expected if the two
drugs were merely additive. Thus GR38032F alone caused a
10% reduction in retches and a 20% reduction in vomits,
dexamethasone caused a similar reduction in retches and a
35% decrease in vomits, but the combination therapy pro-
duced a 65% reduction in retching and 72% reduction in
vomiting.
How dexamethasone acts is unclear. It is well established
that it acts at the hypothalamic level to inhibit the release of
ACTH and thus lower circulating levels of adrenal steroids,
although its anti-emetic activity may not be related to adre-
nal suppression. It has been postulated that dexamethasone
might act by inhibiting prostaglandin synthesis (Rich et al.,
1980); certainly indomethacin can substantially reduce the
emesis evoked by radiation in dogs (Carpenter et al., 1986)
and iboprufen has proved useful in humans (Stryker et al.,
1979). Some cytotoxic drugs such as methotrexate and radia-
tion cause increases in the blood-CSF permeability barriers
(Livrea et al., 1985). The well known action of dex-
amethasone on the blood-brain barrier may therefore be
important in counteracting this effect and reducing the num-
ber of potentially emetic agents that would otherwise enter
the CNS. Although the area postrema is classically outside
the blood-brain barrier we cannot discount the fact that
dexamethasone might have important actions on the vas-
culature of this area and again prevent passage of emetic
agents from the circulation to the chemoreceptor trigger
zone. Our study provides a basis for extending the use of
5HT3 antagonists to combination therapy in the clinical
situation, where GR38032F and dexamethasone, an effective
anti-emetic agent which has beneficial actions in 'nausea',
together may prove useful to the numbers of patients refrac-
tory to GR38032F used alone.
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